Claims:

Claim 1. An amino acid construct comprising any one of an amino acid sequence selected from SEQ ID NOs: 13, 165, 10 to 12, and 14 to 22.

Claim 2. The amino acid construct of claim 1, wherein the amino acid sequence comprises a foldon and a linker sequence.

Claim 3. The amino acid construct of claim 1 or claim 2, wherein the amino acid sequence comprises the sequence set forth in SEQ ID NO: 13 or 165.

Claim 4. A nucleic acid encoding the amino acid construct of any one of claims 1 to 3.

Claim 5. The nucleic acid according to claim 4, comprising a messenger ribonucleic acid (mRNA).

Claim 6. An immunogenic composition comprising the amino acid construct of any one of claims 1 to 3, or the nucleic acid of claim 4 or claim 5.

Claim 7. The immunogenic composition of claim 6, further comprising an adjuvant.

Claim 8. A viral vector comprising a nucleic acid of claim 4 or claim 5.

Claim 9. The viral vector of claim 8, wherein the vector is selected from a recombinant measles virus vector, a vesicular stomatitis virus (VSV) vector, a vaccinia virus vector or an adenovirus vector.

Claim 10. Use of an amino acid construct according to any one of claims 1 to 3, the nucleic acid according to claim 4 or claim 5, the immunogenic composition according to claim 6 or claim 7, or the viral vector according to claim 8 or claim 9, in the manufacture of a medicament for the treatment and/or prevention of sarbecovirus infections.

Claim 11. The use of the amino acid construct, nucleic acid, immunogenic composition or viral vector according to claim 10, wherein the sarbecovirus is selected from the group comprising SARS-CoV, SARS-CoV-2, SARS-CoV-2 B.1.1.7, SARS-CoV-2 B.1.351, SC2r-CoV RaTG13, and SC2r CoV GX-P5L.

Claim 12. A method of making an amino acid construct for use in the manufacture of a medicament for the treatment and/or prevention of sarbecovirus infections, comprising:

a. comparing amino acid sequences from at least two different sarbecovirus spike proteins or fragments thereof;

b. identifying identical amino acids in the sequences from the at least two different sarbecovirus spike proteins or fragments thereof;

c. removing any different amino acids from the sequences of the at least two different sarbecovirus spike proteins or fragments thereof to identify a unique amino acid sequence; and

d. forming the amino construct of the unique amino acid sequence wherein the amino construct has at least 90% sequence identity to the at least two different sarbecovirus Spike proteins, or a fragment thereof.

Claim 13. The method of claim 12, further comprising modifying the unique amino acid sequence with a foldon and a linker sequence.

Claim 14. The method of claim 12 or claim 13, wherein forming the amino construct in step d comprises forming a nucleic acid encoding the amino acid construct.

Claim 15. The method of any one of claims 12 to 14, wherein the amino acid construct or a nucleic acid encoding the amino acid construct is prepared as an immunogenic composition.